Thyroid Eye Disease: Management Across the Spectrum of Severity and Chronicity (CME Webcast)
Activity Description and Purpose
This educational activity aims to provide expert advice on diagnosis, current treatment approaches, and comanagement across the multidisciplinary team to clinicians who currently treat patients with thyroid eye disease or have an interest in managing patients with thyroid eye disease. A focused discussion on comanagement among eye care professionals and an endocrinologist provides practical strategies to optimize patient care. The desired results of this activity are to increase appropriate treatment of chronic TED in practice and to foster competent interdisciplinary collaboration to ensure the best possible outcomes for patients with chronic TED.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Identify patients with thyroid eye disease who would be optimal candidates for treatment with biologic therapies
- Apply evidence to manage thyroid eye disease in patients with chronic disease
|Wendy W. Lee, MD, MS (Chair)|
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Roger A. Dailey, MD
|Andrew R. Harrison, MD|
Department of Ophthalmology and Visual Neurosciences
Department of Otolaryngology, Head and Neck Surgery
Director, Ophthalmic Plastic and Reconstructive Surgery Service
Co-Director, Center for Thyroid Eye Disease
University of Minnesota
Sonalika Khachikian, MD
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Roger A. Dailey, MD, is a consultant for Horizon Therapeutics plc and Viridian Therapeutics, Inc.
Andrew R. Harrison, MD, is a consultant for Horizon Therapeutics plc and RVL Pharmaceuticals, Inc; and is on the speakers bureau for Horizon Therapeutics plc and RVL Pharmaceuticals, Inc.
Sonalika Khachikian, MD, is a consultant for Horizon Therapeutics plc; is on the speakers bureau for Horizon Therapeutics plc; and is on the advisory board of Novo Nordisk A/S*.
Wendy W. Lee, MD, MS, is a consultant for Allergan, Horizon Therapeutics plc, Mallinckrodt*, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc.
* The financial relationship existed during the past 24 months but has now ended.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Horizon Therapeutics USA, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Horizon Therapeutics USA, Inc.
©2023 MedEdicus LLC. 304.3
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation